Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aska Pharmaceutical Holdings Co. Ltd. (4886:JPX), powered by AI.
Aska Pharmaceutical Holdings Co. Ltd. is currently trading at ¥2,307. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aska Pharmaceutical Holdings Co. Ltd. on Alpha Lenz.
Aska Pharmaceutical Holdings Co. Ltd.'s P/E ratio is 12.8.
“Aska Pharmaceutical Holdings Co. Ltd. trades at a P/E of 12.8 (undervalued) with solid ROE of 8.0%.”
Ask for details →Aska Pharmaceutical Holdings Co. Ltd. is a prominent player in the pharmaceutical industry, focused on developing and manufacturing a wide array of medicinal products. Headquartered in Japan, Aska Pharmaceutical emphasizes the production of prescription drugs, over-the-counter medications, and active pharmaceutical ingredients. The company plays a critical role in the healthcare sector by supplying therapeutic solutions for various medical needs, including specialty areas such as endocrinology, urology, and obstetrics and gynecology. Aska Pharmaceutical Holdings Co. Ltd. stands out for its commitment to research and development, continuously aiming to innovate and improve treatment options available to healthcare professionals and patients alike. The firm operates within a highly regulated industry, emphasizing quality and safety in all of its processes. In a constantly evolving market, Aska Pharmaceutical leverages its expertise and infrastructure to address both domestic and international pharmaceutical demands, contributing significantly to the advancement of global health standards.
“Aska Pharmaceutical Holdings Co. Ltd. trades at a P/E of 12.8 (undervalued) with solid ROE of 8.0%.”
Ask for details →Aska Pharmaceutical Holdings Co. Ltd. (ticker: 4886) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,632 employees. Market cap is $65.4B.
The current price is 2,307 with a P/E ratio of 12.82x and P/B of 1x.
ROE is 8.02% and operating margin is 8.31%. Annual revenue is $64.1B.